원텍
Financials
Valuation Metrics
원텍's Market Cap is ₩4652B. At end of 2025 it was ₩6919B. Ranked #472 of 2,436 in KR market (top 19%), #173 of 1,649 on KOSDAQ (top 10%), #14 of 96 in Health Care Equipment & Services (top 15%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 465.15B KRW | KR#472/2,436 Sec#14/96 |
| Revenue | 159.67B KRW | KR#1,131/2,436 Sec#15/96 |
| Net Income | 33.74B KRW | KR#475/2,436 Sec#11/96 |
| Total Assets | 227.28B KRW | KR#1,201/2,436 Sec#31/96 |
| Net Assets | 163.41B KRW | KR#1,045/2,436 Sec#27/96 |
| Employees | 228 | KR#994/2,436 Sec#30/96 |
| Value | ||
| P/E | 13.79x | KR#924/2,436 Sec#26/96 |
| P/B | 2.85x | KR#2,097/2,436 Sec#78/96 |
| P/S | 2.91x | KR#1,999/2,436 Sec#62/96 |
| EV/EBITDA | 9.51x | KR#572/2,436 Sec#17/96 |
| FCF Yield | 10.74% | KR#595/2,436 Sec#12/96 |
| Profitability | ||
| ROE | 20.65% | KR#120/2,436 Sec#5/96 |
| ROA | 14.85% | KR#76/2,436 Sec#7/96 |
| Op. Margin | 30.27% | KR#54/2,436 Sec#3/96 |
| Revenue Growth | 7.57% | KR#1,045/2,436 Sec#50/96 |
| Earnings Growth | -12.43% | KR#1,000/2,436 Sec#39/96 |
| Financial Health | ||
| Debt Ratio | 139.08% | KR#1,018/2,436 Sec#51/96 |
| Total Debt | 18.72B KRW | KR#1,377/2,436 Sec#43/96 |
| FCF | 49.94B KRW | KR#297/2,436 Sec#4/96 |
| Cash | 24.12B KRW | KR#1,129/2,436 Sec#26/96 |
| Current Ratio | 3.05x | KR#603/2,436 Sec#37/96 |
| Net Debt/EBITDA | -0.11x | KR#664/2,436 Sec#26/96 |
| Dividend | ||
| Div. Yield | 1.03% | KR#1,142/2,436 Sec#35/96 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/96 |
| Performance | ||
| 1Y Return | -57.54% | KR#2,204/2,436 Sec#81/96 |
| 1M Return | -14.59% | KR#2,009/2,436 Sec#79/96 |
| From 52W High | -61.06% | KR#1,761/2,436 Sec#65/96 |
| 1Y MDD | -67.12% | KR#1,797/2,436 Sec#63/96 |
| Trading | ||
| Volume | 646,205 shares | KR#211/2,436 Sec#5/96 |
| Foreign Own. | 3.56% | KR#951/2,436 Sec#35/96 |
| Per Share | ||
| EPS | 375 KRW | KR#1,030/2,436 Sec#28/96 |
| BPS | 1,831 KRW | KR#2,078/2,436 Sec#70/96 |
Company Info
Established in 1999 as a specialized medical device company, Wontech is headquartered in Yuseong-gu, Daejeon Metropolitan City, having completed a merger with Daishin Balance No. 8 Special Purpose Acquisition Company in 2022. It primarily manufactures and sells skin aesthetics lasers and energy-based medical devices, including Oligio, Picocare, and Lavieen, actively exporting to Asia, Europe, the Middle East, and South America. The company diversifies its product lineup through RF and HIFU technology development and strengthens competitiveness by developing Monopolar RF Oligio.